| Project 9: Systems-based integration and analysis of a deeply phenotyped GBM cohort correlating to 'extreme' and 'poor' responding patients |
|
Location: Royal College of Surgeons in Ireland Principle Investigator: Prof Jochen Prehn Collaborators: Dr Alexander Kel (geneXplain, Germany), Dr Ahmed Idbaih (ICM Institute for Brain and Spinal Cord, France) |
| Project 10: Multi-scale mathematical modelling of non-Darwinian dynamics in therapy-induced drug resistance in GBM |
|
Location: Royal College of Surgeons in Ireland Principle Investigator: Dr Marc Sturrock Collaborators: Dr Alexander Kel (geneXplain, Germany) |
| Project 11: Single-cell RNA-sequencing in the context of space and time to interrogate tumour microenvironment (TME) impact on therapy response |
|
Location: Vlaams Instituut voor Biotechnologie, Belgium Principle Investigator: Prof Diether Lambrechts Collaborators: Dr Jurgen del Favero (Agilent Technologies, Belgium) |
| Project 12: Interrogating intratumoural heterogeneity and disease resistance mechanisms by scRNA-Seq in intracranial human GBM PDX models |
|
Location: Luxembourg Institute of Health, Luxembourg Principle Investigator: Prof Simone Niclou Collaborators: Dr Andreas Kremer (Information Technology for Translational Medicine [ITTM], Luxembourg) |
| Project 13: Integrative genomic analysis of drug resistance in GBM using advanced 2D and 3D models |
|
Location: Erasmus University Rotterdam, The Netherlands Principle Investigator: Prof Sieger Leenstra Collaborators: Dr Jos Joore (Pepscope, The Netherlands and Mimetas, The Netherlands) |
| Project 14: Modelling therapeutic resistance in GBM using multi-omic computational models |
|
Location: geneXplain, Germany Principle Investigator: Dr Alexander Kel Collaborators: Dr Martine Lamfers (Erasmus University Rotterdam, The Netherlands), Prof Diether Lambrechts (Vlaams Instituut voor Biotechnologie, Belgium) |
| Project 15: Systems methods for analysis of heterogeneous GBM datasets towards elucidation of inter-tumoural resistance pathways and therapeutic new targets |
|
Location: ITTM S.A., Luxembourg Principle Investigator: Dr Andreas Kremer Collaborators: Prof Diether Lambrechts (Vlaams Instituut voor Biotechnologie, Belgium), Dr Verena Murphy (Cancer Trials Ireland), Dr Martine Lamfers (Erasmus University Rotterdam, The Netherlands) |